dr. MICHAEL M. WICK is Chairman and Chief Executive Officer of
Telik, Inc. He joined Telik in 1997 from CV Therapeutics, Inc.,
where he was Senior Vice President of Research and Development.
Prior to joining CV Therapeutics, Dr. Wick was Executive Director
of Oncology/Immunology and Clinical Research at Lederle
Laboratories, a division of American Cyanamid, where he also
directed the Cyanamid/Immunex joint oncology research program.
Dr. Wick began his career at Harvard Medical School, where he was
an Associate Professor. He also was Chief of the Melanoma Clinic
and Laboratory of Molecular Dermatological Oncology at the Dana
Farber Cancer Institute. Dr. Wick holds a PhD in Chemistry from
Harvard University and an MD from Harvard Medical School. Profile
TWST: What has gone on over the past year that investors should
Dr. Wick: Telik has had a very exciting year. We presented
positive clinical data with our lead product candidate,